Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Amlexanox (AA673) 是一种特异性的 IKKε和 TBK1抑制剂,其 IC50=1-2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 285 | 现货 | ||
25 mg | ¥ 453 | 现货 | ||
50 mg | ¥ 663 | 现货 | ||
100 mg | ¥ 828 | 现货 | ||
500 mg | ¥ 1,980 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 410 | 现货 |
产品描述 | Amlexanox (AA673) is an anti-aphthous ulcer drug. Amlexanox inhibits the synthesis and release of inflammatory mediators, including leukotrienes and histamine, from mast cells, neutrophils, and mononuclear cells. Amlexanox also acts as a leukotriene D4 antagonist and a phosphodiesterase inhibitor. Amlexanox decreases the time ulcers take to heal as well as the pain associated with the ulcers. |
靶点活性 | TBK1:1-2 μM, IKKε:1-2 μM |
体外活性 | AmLexanox increases phosphorylation of TBK1 on Ser172 in 3T3-L1 adipocytes, and blocks polyinosinic:polycytidylic acid (poly I:C)-stimulated phosphorylation of interferon responsive factor-3 (IRF3), a presumed substrate of IKKε and TBK1[1]. AmLexanox potently inhibits the release of histamine and leukotrienes from mast cells, basophils and neutrophils in in vitro settings, possibly through increasing intracellular cyclic AMP content in inflammatory cells, a mem-brane-stabilising effect or inhibition of calcium influx[2]. In primary bone marrow derived macrophages (BMMs), amLexanox inhibits osteoclast formation and bone resorption. At the molecular level, amLexanox suppresses RANKL-induced activation of nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPKs), c-Fos and NFATc1. AmLexanox decreases the expression of osteoclast-specific genes, including TRAP, MMP9, Cathepsin K and NFATc1[3]. |
体内活性 | AmLexanox (100 mg/kg, p.o.) prevents and reverses diet-induced or genetic obesity, and produces reversible weight loss in obese mice. AmLexanox also causes a significant decrease in adipose tissue mass in these mice, and an increase in circulating adiponectin. AmLexanox (25 mg/kg) significantly improves insulin sensitivity in mice with established DIO,and after four weeks of treatment, amLexanox produces marked improvements in glucose[1]. AmLexanox before the first application of the paste and at each has been shown to suppress both immediate and evaluation thereafter. A categorical scale is also delayed-type hypersensitivity reactions[2]. AmLexanox (20?mg/kg) enhances osteoblast differentiation of BMSCs. In ovariectomized (OVX) mouse model, amLexanox prevents OVX-induced bone loss by suppressing osteoclast activity[3]. |
激酶实验 | The in vitro kinase assays is performed by incubating purified kinase (IKKε or TBK1) in kinase buffer containing 25 mM Tris (pH7.5), 10 mM MgCl2, 1 mM DTT, and 10 μM ATP for 30 minutes at 30°C in the presence of 0.5 μCi γ-[32P]-ATP and 1 μg MBP per sample as a substrate. The kinase reaction is stopped by adding 4x sodium dodecyl sulfate (SDS) sample buffer and boiling for 5 minutes at 95°C. Supernatants are resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and analyzed by autoradiography using a Typhoon 9410 phosphorimager. |
细胞实验 | To examine cell proliferation, a Cell Counting Kit-8 is used according to the manufacturer's instructions. BMMs are seeded at a density of 5×103 cells/well in 96-well plates. After 24?hours, cells are treated with different concentrations of AmLexanox (0, 1.5, 3, 6, 12, 25?μM) every 2 days in the presence of M-CSF (30?ng/mL) for 7 days. After 1, 3, 5 and 7 days, the culture medium is replaced by the medium containing 10% CCK-8 and cells are incubated at 37°C for an additional 2?h. The absorbance is then measured at a wavelength of 450?nm on an ELX800 absorbance microplate reader. |
别名 | 氨来呫诺, CHX3673, Amoxanox, 氨来诺, AA673 |
分子量 | 298.29 |
分子式 | C16H14N2O4 |
CAS No. | 68302-57-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 29.8 mg/mL(100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.3524 mL | 16.7622 mL | 33.5244 mL | 83.8111 mL |
5 mM | 0.6705 mL | 3.3524 mL | 6.7049 mL | 16.7622 mL | |
10 mM | 0.3352 mL | 1.6762 mL | 3.3524 mL | 8.3811 mL | |
20 mM | 0.1676 mL | 0.8381 mL | 1.6762 mL | 4.1906 mL | |
50 mM | 0.067 mL | 0.3352 mL | 0.6705 mL | 1.6762 mL | |
100 mM | 0.0335 mL | 0.1676 mL | 0.3352 mL | 0.8381 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Amlexanox 68302-57-8 Angiogenesis Immunology/Inflammation NF-Κb Others Tyrosine Kinase/Adaptors IL Receptor FGFR IκB/IKK 氨来呫诺 CHX-3673 AA 673 I kappa B kinase inhibit IKK Inhibitor CHX3673 IκB kinase Amoxanox 氨来诺 CHX 3673 AA-673 AA673 inhibitor